David Dicesar, MD
Endocrinology, Diabetes & Metabolism · East Syracuse, NYNPI 1689837734
Payments from drug & device makers
Across 592 payments — averaging $431.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$160K
- Dexcom, Inc.$51K
- Sanofi-aventis U.S. LLC$27K
- Johnson & Johnson$10K
- IBSA Pharma Inc.$2K
- Lilly USA, LLC$824
- plus $5K from 36 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 206 | $160,134 |
| Dexcom, Inc. | 47 | $50,562 |
| Sanofi-aventis U.S. LLC | 38 | $27,433 |
| Johnson & Johnson | 19 | $9,632 |
| IBSA Pharma Inc. | 12 | $1,653 |
| Lilly USA, LLC | 59 | $824 |
| Amgen | 26 | $627 |
| Medtronic(2 entities) | 9 | $552 |
| AstraZeneca(2 entities) | 18 | $528 |
| Boehringer Ingelheim | 22 | $359 |
| Abbott | 15 | $282 |
| Ascendis Pharma Endocrinology Inc | 6 | $252 |
| Novartis | 11 | $240 |
| Pfizer | 12 | $231 |
| Tandem Diabetes Care, Inc. | 7 | $170 |
| Bayer | 9 | $165 |
| Corcept Therapeutics | 8 | $161 |
| Mannkind Corporation | 8 | $153 |
| Xeris Pharmaceuticals, Inc. | 7 | $131 |
| Recordati_rare_diseases_inc. | 5 | $109 |
| BETA Bionics, Inc. | 5 | $108 |
| AbbVie | 7 | $108 |
| Radius Health, Inc. | 5 | $93 |
| Amphastar Pharmaceuticals, Inc. | 4 | $77 |
| Sanofi | 1 | $72 |
| Amneal Pharmaceuticals LLC | 3 | $64 |
| Sequel Med Tech, LLC | 3 | $60 |
| Insulet Corporation | 2 | $43 |
| Ultragenyx Pharmaceutical Inc. | 2 | $42 |
| Amarin Pharma, Inc. | 2 | $37 |
| Madrigal Pharmaceuticals | 1 | $32 |
| GSK | 2 | $30 |
| Kyowa Kirin, Inc. | 1 | $29 |
| Cequr Corporation | 2 | $26 |
| Almatica Pharma LLC | 1 | $25 |
| Currax Pharmaceuticals LLC | 1 | $25 |
| Chiesi USA, Inc. | 1 | $23 |
| Exact Sciences | 1 | $20 |
| Tolmar, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
| Merck | 1 | $11 |
How this compares
$255,169 in reported general payments places this provider in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in East Syracuse
- Steven ZygmontEast Syracuse$167K
- Robert BuschAlbany$9.1M
- Anastasios ManessisNew York$4.4M
- Ruth WeinstockSyracuse$3.1M
- Adi CohenNew York$2.5M
- Ajay ChaudhuriBuffalo$2.4M
- Carol LevyNew York$2.2M
- Mishaela RubinNew York$2M
- Kenneth HershonNew Hyde Park$1.9M
- Michael ShanikSmithtown$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.